Emergence of Cancer Drug Resistance and Focus on Rare Diseases Found in 2018 Published Research

Genomenon Releases New Report on Emerging Genomic Variants in 2018 Scientific Research

ANN ARBOR, MICHIGAN – January 17, 2019 - Genomenon® has released a research report detailing the top emerging genomic variants in 2018. A variant is defined as a DNA mutation; this information is used in Precision Medicine to diagnose and treat disease. The report was compiled using the research data found in the Mastermind® Genomic Search Engine.

Compared to the 2017 Variant Report, this year’s data showed a continued trend of studies and new discoveries detailing variants that are becoming increasingly resistant to drugs. Also notable: an increasing number of emergent variants were found in non-cancer diseases.

The report includes:

• Top 12 Emerging Variants in Genomic Literature 2018 - Cancer
• Top 16 Emerging Variants in Genomic Literature 2018 - Non-Cancer
• Top 20 Genes in Genomic Literature 2018
• Top 20 Diseases in Genomic Literature 2018

The data reveals:

• A shift of focus away from previously well-characterized variants that have been known for many years
• A shift from a singular focus on cancer towards the inclusion of an increasingly broad array of variants in many more types of genes
• A greater number of constitutional diseases, including rare genetic disorders

The Mastermind Genomic Search Engine is an evidence-based interpretation tool which provides immediate insight into the full text of millions of genomic articles and supplemental data for every disease, gene, and variant found in the literature. Mastermind is used by hundreds of diagnostic labs around the world to accelerate genomic interpretation, and by pharmaceutical companies to provide a comprehensive genomic landscape for any disease. The report is available here: Genomenon Research Report: Emerging Genomic Variants in 2018

This report was also posted on EnlightenBio in cooperation with its founder, Brigitte Ganter.

‍

About Genomenon

Genomenon powers evidence-based genomics for faster; more comprehensive diagnosis and treatment decisions. Their flagship product, the Mastermind Genomic Search Engine provides immediate insight into the published genomic research for every disease, gene, and variant found in the literature.

Used by hundreds of diagnostic labs around the world, Mastermind accelerates genomic interpretation by providing unique insight into genomic relationships found in the full text of millions of scientific articles.

Pharmaceutical researchers license the Mastermind database for a comprehensive genomic landscape associated with any given disease – to identify and prioritize genomic biomarkers for drug discovery and clinical trial targets. For more information, visit www.genomenon.com.